This is the fifth issue of a monthly index of listed research peptide prices, following the May, June, July and August issues.
September's cuts went to one corner of the market. Listings of tirzepatide, retatrutide and semaglutide were cut three times as often as everything else, led by one vendor that took a quarter off its whole GLP-1 line in a single day. The rest of the market was quieter than in August: 85% of tracked listings ended the month at the price they started it, and the median compound did not move.
What was measured
Prices are compared listing against listing, between the first week of September and the last. A listing counts only if it was in stock and priced in both.
- Panel: 1,162 listings, spanning 85 compounds across 24 vendors.
- Prices are raw list prices, before any coupon or site-wide discount.
- Per-milligram figures cover vial and liquid products sold by mass. Capsules, sprays and products dosed by volume are excluded.
Full definitions are on the methodology page.
Prices stayed sticky for a fifth month
Of the 1,162 listings, 990 (85%) ended September at exactly the price they started it. That is the fifth consecutive month in the same band: 78% in May, 88% in June, 76% in July, 83% in August, 85% in September.
Among the 172 listings that did move, 146 fell and 26 rose, and the median mover fell 11.1%.
As of September 30, 2026, the median listed price across the compounds in the index was $4.80 per milligram. That is ten cents below August's figure, but the difference comes from what the index covers rather than from prices: it tracked 33 vendors at the end of September against 23 at the end of August, and on the listings tracked at both month-ends the median compound's price did not change. Half of all listings fell between $2.77 and $7.00 per milligram.
Fourteen of the 24 vendors in the panel ended September with every tracked price exactly where it began, up from 11 of 21 in August.
The cuts landed on GLP-1 agonists
Of the 227 tracked listings of tirzepatide, retatrutide and semaglutide, 62 fell in September, or 27%. Across everything else in the index, 84 of 935 listings fell, or 9%. Only seven of the 227 rose.
- EZ Peptides cut all 26 of its tracked tirzepatide, retatrutide and semaglutide listings on September 16, by a median of 26%, and left its other 47 tracked listings unchanged. Single vials fell between 23% and 47% and ten-vial kits between 2% and 28%. Its 10 mg tirzepatide vial went from $5.30 to $2.80 per milligram. The store lists the new figures as regular prices, not as a sale.
- HLX Labs cut 19 of its 42 tracked listings in four steps between September 9 and September 23, by a median of 22%, after cutting 19 in August. Its ten-vial retatrutide kit fell 43%, from $3.50 to $1.99 per milligram, and its 10 mg tirzepatide 34%, from $5.00 to $3.30.
- Ascension Peptides cut 15 of its 39 tracked listings, most of them on September 7, and raised three. Its tirzepatide, which more than doubled in August, came down from $10.50 to $8.00 per milligram, then went back up to $9.00 on September 30.
- Platinum Lion Peptides cut 12 of its 57 tracked listings on September 6, by a median of 7.5%, and Sigma Compounds cut four on September 9, by a median of 15%. Most of both vendors' cuts were to the same three compounds.
EZ Peptides accounts for about a third of the index's net decline for the month. No vendor carried September the way Peptide Giants carried August: having cut 71 listings in August, it changed one in September.
One catalog-wide cut, two sales and one increase
- TrustedPeps cut all 21 of its tracked listings, by a median of 20%, most of them on September 24. Its 20 mg tirzepatide fell from $1.75 to $1.00 per milligram.
- BioInfinity cut all 32 of its tracked listings by about 10% on September 18, then restored nearly all of its earlier prices on October 1 (a two-week sale rather than a repricing).
- Glacier Aminos ran three short sales across much of its catalog, starting September 4, September 19 and September 26, each reversed within days, and most of its prices were back at their regular level on October 1.
- By Oneday repriced most of its catalog six times in September, alternating between a few days at full price and runs at a sale price. It started and ended the month on the same sale price, so its 39 tracked listings show no change.
- Alpha Peptides went the other way, raising 22 of its 23 tracked listings by a median of 5% on September 7.
The largest single increase was SS-31 at Ascension Peptides, up 33% from $6.00 to $8.00 per milligram. The largest decrease was sermorelin at HLX Labs, down 50% from $12.00 to $6.00 per milligram on a 5 mg vial.
The gap between vendors held steady
Among compounds carried by five or more vendors, the median one costs about five times as much at its dearest listing as at its cheapest, as of September 30, 2026. That is wider than the three to four times reported for August because the index now covers more vendors, which puts more listings at both extremes. Among vendors tracked at both month-ends, the gap narrowed for nine compounds, widened for eight and did not change for 22.
These are the widest, as of September 30, 2026.
- 5-Amino-1MQ ranged from $0.64 to $13.80 per milligram across 42 listings from 25 vendors, the widest gap in the index. The low end is TrustedPeps' 50 mg vial after its September cut. The high end is a 5 mg vial from Licensed Peptides, new to the index this month.
- Tirzepatide ranged from $0.87 to $11.00 per milligram across 144 listings from 32 vendors, the same prices at both ends as in August.
- Retatrutide ranged from $1.25 to $15.00 per milligram across 178 listings from 33 vendors.
Still no price response to the FDA vote
Ten weeks after FDA's Pharmacy Compounding Advisory Committee recommended six of seven peptides for the 503A compounding list, the five measurable recommended peptides again repriced no more often than the rest of the market: 15% of their 150 tracked listings changed price in September, against 15% of everything else, and the median change was zero in both. The four-week reading found the same.
FDA has not opened rulemaking on the list. As of October 1, 2026, the Federal Register carries no FDA document on the 503A bulk drug substances list since the meeting.
What this does not measure
- It measures listed prices, not transaction prices. Coupons, first-order discounts and bulk terms are not applied.
- It does not test products, verify purity, or assess any vendor's certificates of analysis.
- Vendor and listing counts describe what this index covers, not the size of the market.
Sources
- PeptideScouter methodology, covering index construction, normalization and known limits.
- PeptideScouter price index, the live per-milligram figures this report is drawn from.
- Peptide Price Index, August 2026, the previous issue.
- The July 2026 FDA Peptide Vote Has Not Moved Prices, the four-week reading on the recommended peptides.
- Federal Register (FDA compounding documents, checked October 1, 2026 for any rulemaking following the vote).
- Price index data, September 2026 (CSV), covering per-compound medians, listing and vendor counts and spreads as of September 30, 2026, with the summary figures and column definitions. Every issue's files are listed at /data/price-index.
- Zenodo archive of the September 2026 files, DOI 10.5281/zenodo.23091032. The series DOI 10.5281/zenodo.22262438 resolves to the newest issue.
- Underlying data is PeptideScouter's own daily price archive, collected from public vendor storefronts.
All figures in this report are as of September 30, 2026, computed from the archive as of publication.